Designing meningitis vaccines

Journal of the Royal College of Physicians of London

Volumn 34, Issue 2, 2000, Pages 163-168

  Buttery, Jim P ^a   Moxon, E Richard ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; DRUG CARRIER; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; DRUG CONJUGATION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGENICITY; MENINGITIS; NEISSERIA MENINGITIDIS; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BACTERIAL VACCINES; CARRIER PROTEINS; CHILD, PRESCHOOL; DRUG DESIGN; ENGLAND; HAEMOPHILUS INFLUENZAE TYPE B; HUMANS; INFANT; INFANT, NEWBORN; MENINGITIS, BACTERIAL; NEISSERIA MENINGITIDIS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; WALES;

EID: 0034034971     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981;3:S1-17
2. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994;265:1385-7.
3. Klein DL, Ellis RW. Conjugate vaccines against Streptococcus pneumoniae. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS (eds). New generation vaccines, Second ed. New York: Marcel Decker, 1997: 503-26.
4. Moxon ER. Haemophilus influenzae. In: Mandell GL, Bennett JE, Dolin R (eds). Mandell, Douglas and Bennett's Principles and practice of infectious diseases, Fourth ed. New York: Churchill Livingstone, 1995: 2039-44.
5. Rushdie A. Laboratory reports to CDSC. Public Health Laboratory Service, Colindale, London. 1998.
6. Office of National Statistics. Mid-year population estimates. London, 1998.
7. Peltola H, Kallio MJ, Unkila Kallio L. Reduced incidence of septic arthritis in children by Haemophilus influenzas type-b vaccination. Implications for treatment. J Bone Joint Surg Br 1998;80:471-3.
8. Barbour ML, Mayon White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995;171:93-8.
9. Mulholland K, Hilton S, Adegbola R, Usen S, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-7.
10. Personal communication. Heath PT. British Paediatric Surveillance Unit data. 1998.
11. Finne J, Bitter Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987;138:4402-7.
12. Leach A, Twumasi PA, Kumah S, Banya WS, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4.
13. Public Health Laboratory Service. Meningococcal disease in university students. CDR Weekly 1998;8:49-52.
14. Peltola H. Meningococcal vaccines. Current status and future possibilities. Drugs 1998;55:347-66.
15. George RC, Johnson AP, Speller DC, Efstratiou A, et al. Serogroups/types and antibiotic resistance of referred isolates of Streptococcus pneumoniae: 1993 to 1995. Commun Dis Rep CDR Rev 1997;7:R159-64.
16. Butler JC. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. Microb Drug Resist 1997;3:125-9.
17. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-90.
18. Mills OF, Rhoads GG. The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines. J Clin Epidemiol 1996;49:631-6.
19. Butler JC, Breiman RF, Campbell JF, Lipman HB, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270:1826-31.
20. Fine MJ, Smith MA, Carson CA, Meffe F, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77
21. Farr BM, Johnston BL, Cobb DK, Fisch MJ, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995;155:2336-40.
22. Daum RS, Hogerman D, Rennels MB, Bewley K, et al. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 1997;176:445-55.
23. Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-6.
24. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-4.
25. Black S. Preliminary announcement. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 25, 1998, San Diego.
26. Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann NY Acad Sci 1995;754:35-47
27. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998;66:2093-8.
28. Peltola H, Eskola J, Kayhty H, Takala AK, Makela PH. Clinical comparison of the Haemophilus influenzae type B polysaccharide-diphtheria toxoid and the oligosaccharide-CRM-197 protein vaccines in infancy. Arch Pediatr Adolesc Med 1994;148:620-5.
29. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992;120:184-9.
30. Wenger JD, Booy R, Heath PT, Moxon ER. Epidemiological impact of conjugate vaccines on invasive disease caused by Haemophilus influenzae type b. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, (eds). New generation vaccines, Second ed. New York: Marcel Decker, 1997: 489-502.
31. Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996;98:2308-14.